Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately 30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease and therefore as a target for therapy.
Publication type:Research Problem
Published:
Language:English
Licence:
CC BY 4.0
Peer Reviews (This Version): (0)
Red flags:
(0)
Actions
Download:
Sign in for more actionsSections
Research topics above this in the hierarchy
Funders
No sources of funding have been specified for this Research Problem.
Conflict of interest
This Research Problem does not have any specified conflicts of interest.